英夫利昔单抗治疗强直性脊柱炎疗效与安全性的Meta分析
发布时间：2018-09-03 17:33
【摘要】：目的系统评价英夫利昔单抗治疗强直性脊柱炎的疗效与安全性。方法在Pub Med、循证医学数据库、Elsevier、Springer、中国知网、维普、万方等数据库,检索1999年11月至2016年6月发表的英夫利昔单抗联合甲氨蝶呤对比柳氮磺胺吡啶联合甲氨蝶呤或英夫利昔单抗对比安慰剂治疗强直性脊柱炎的随机对照临床试验,以有效率和不良反应发生率为结局指标。提取资料后,对符合纳入标准的文献利用Cochrane系统评价手册5.2和Rev Man5.2软件进行质量分析和Meta分析。结果共纳入10篇文献,996例研究对象。联合用药和单独用药试验组的有效率均显著高于对照组(分别为RR=1.77,95%CI:1.44~2.17,P0.000 01和RR=2.84,95%CI:2.21~3.65,P0.000 01)。不良反应方面,联合用药的两组无显著差异(P0.05),而单独用药中试验组的炎性指标异常发生率高于对照组(P≤0.05)。结论英夫利昔单抗单独用药或联合甲氨蝶呤治疗强直性脊柱炎,相比传统药物的疗效更明确,安全性较好。
[Abstract]:Objective to evaluate the efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Methods Elsevier Springer, China knowledge Network, Weip, Wanfang and other databases were used in Pub Med, Evidence-based Medicine Database. To retrieve the randomized controlled clinical trial of infliximab combined with methotrexate versus sulfamyridine combined with methotrexate or infliximab in the treatment of ankylosing spondylitis published from November 1999 to June 2016. Efficacy and incidence of adverse reactions were taken as outcome indicators. After extracting the data, the quality analysis and Meta analysis were carried out by using Cochrane system evaluation manual 5.2 and Rev Man5.2 software. Results A total of 996 subjects were included in 10 articles. The effective rate of the combined drug group and the single drug group were significantly higher than that of the control group (RR=1.77,95%CI:1.44~2.17,P0.000 01 and RR=2.84,95%CI:2.21~3.65,P0.000 01, respectively). There was no significant difference in adverse reactions between the two groups (P0.05), but the incidence of abnormal inflammatory indexes in the test group was higher than that in the control group (P 鈮，
本文编号：2220689
[Abstract]:Objective to evaluate the efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Methods Elsevier Springer, China knowledge Network, Weip, Wanfang and other databases were used in Pub Med, Evidence-based Medicine Database. To retrieve the randomized controlled clinical trial of infliximab combined with methotrexate versus sulfamyridine combined with methotrexate or infliximab in the treatment of ankylosing spondylitis published from November 1999 to June 2016. Efficacy and incidence of adverse reactions were taken as outcome indicators. After extracting the data, the quality analysis and Meta analysis were carried out by using Cochrane system evaluation manual 5.2 and Rev Man5.2 software. Results A total of 996 subjects were included in 10 articles. The effective rate of the combined drug group and the single drug group were significantly higher than that of the control group (RR=1.77,95%CI:1.44~2.17,P0.000 01 and RR=2.84,95%CI:2.21~3.65,P0.000 01, respectively). There was no significant difference in adverse reactions between the two groups (P0.05), but the incidence of abnormal inflammatory indexes in the test group was higher than that in the control group (P 鈮，
本文编号：2220689
本文链接：https://www.wllwen.com/yixuelunwen/nfm/2220689.html
最近更新
教材专著
